Skip to content

Biodesix, Inc. BDSX Current ratio

Current ratio at other companies

NeoGenomics logo
NeoGenomicsNEO
4.4×+2.4×
Veracyte logo
VeracyteVCYT
9.3×+4.2×
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
3.4×+0.4×
Personalis, Inc. logo
Personalis, Inc.PSNL
6.6×-0.3×
Guardant Health logo
Guardant HealthGH
4.7×+0.6×
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
3.3×+1.6×

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s current ratio?
Biodesix, Inc. (BDSX) reported current ratio of 2.8× in Q1 2026.
How has Biodesix, Inc.'s current ratio changed year-over-year?
Biodesix, Inc.'s current ratio increased by 26.9% year-over-year, from 2.2× to 2.8×.
What is the long-term trend for Biodesix, Inc.'s current ratio?
Over 5 years (2020 to 2025), Biodesix, Inc.'s current ratio has grown at a -7.0% compound annual growth rate (CAGR), from 2.7× to 1.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.